Tominaga Kumi, Hongo Nobuko, Fujishita Mayuko, Takahashi Yu, Adachi Yuki
AstaReal Co., Ltd., 55 Yoko-hoonji, Kamiichi-machi, Nakaniikawa-gun, Toyama 930-0397, Japan.
J Clin Biochem Nutr. 2017 Jul;61(1):33-39. doi: 10.3164/jcbn.17-35. Epub 2017 Jun 20.
Astaxanthin is a carotenoid with potent antioxidant and anti-inflammatory activity. To evaluate the anti-inflammatory effect of astaxanthin on skin deterioration, we confirmed its role in epidermal-dermal interactions . Astaxanthin treatment suppressed ultraviolet B (UVB)-induced inflammatory cytokine secretion in keratinocytes, and matrix metalloproteinase-1 secretion by fibroblasts cultured in UVB-irradiated keratinocyte medium. To verify these findings, we conducted a 16-week clinical study with 65 healthy female participants. Participants were orally administered either a 6 mg or 12 mg dose of astaxanthin or a placebo. Wrinkle parameters and skin moisture content significantly worsened in the placebo group after 16 weeks. However, significant changes did not occur in the astaxanthin groups. Interleukin-1α levels in the stratum corneum significantly increased in the placebo and low-dose groups but not in the high-dose group between weeks 0 and 16. This study was performed in Japan from August to December, when changing environmental factors, such as UV and dryness, exacerbate skin deterioration. In conclusion, our study suggests that long-term prophylactic astaxanthin supplementation may inhibit age-related skin deterioration and maintain skin conditions associated with environmentally induced damage via its anti-inflammatory effect. (UMIN Clinical Trials Registry ID: UMIN000018550).
虾青素是一种具有强大抗氧化和抗炎活性的类胡萝卜素。为了评估虾青素对皮肤老化的抗炎作用,我们证实了其在表皮-真皮相互作用中的作用。虾青素处理可抑制角质形成细胞中紫外线B(UVB)诱导的炎性细胞因子分泌,以及在UVB照射的角质形成细胞培养基中培养的成纤维细胞分泌基质金属蛋白酶-1。为了验证这些发现,我们对65名健康女性参与者进行了一项为期16周的临床研究。参与者口服6毫克或12毫克剂量的虾青素或安慰剂。16周后,安慰剂组的皱纹参数和皮肤水分含量显著恶化。然而,虾青素组未出现显著变化。在0至16周期间,安慰剂组和低剂量组角质层中的白细胞介素-1α水平显著升高,而高剂量组未升高。本研究于8月至12月在日本进行,此时紫外线和干燥等环境因素变化会加剧皮肤老化。总之,我们的研究表明,长期预防性补充虾青素可能通过其抗炎作用抑制与年龄相关的皮肤老化,并维持与环境诱导损伤相关的皮肤状况。(UMIN临床试验注册编号:UMIN000018550)